Gene Technologies for Medicines: Public and Business Demands


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Тек жазылушылар үшін

Аннотация

At the present time, gene technologies play a key part in the development of new approaches to the diagnostics and therapy of diseases. Russian scientists have already successfully introduced efficient preparations based on multiclonal antibodies into practice and have advanced developments in the fields of CAR-T therapy and gene-therapy preparations on the basis of recombinant adenoassociated viruses. Some gene diagnostic tools, which essentially improve the efficiency of medical care due to the personalized approach to the therapy of diseases, are also put into practice. The successful introduction of innovative technologies and contemporary methods of diagnostics and therapy is impossible without cooperation between academic science and business. The companies providing the conditions for cooperation with academic science and engagement of specialists of different profiles have hastened the mass introduction of gene technologies and, therefore, the defeat over many earlier incurable socially significant diseases.

Авторлар туралы

D. Morozov

BIOCAD Biotechnological Company, poselok Strel’na

Хат алмасуға жауапты Автор.
Email: morozov@biocad.ru
Ресей, St. Petersburg, 198515

R. Ivanov

BIOCAD Biotechnological Company, poselok Strel’na

Хат алмасуға жауапты Автор.
Email: ivanov@biocad.ru
Ресей, St. Petersburg, 198515

P. Gershovich

BIOCAD Biotechnological Company, poselok Strel’na

Хат алмасуға жауапты Автор.
Email: gershovich@biocad.ru
Ресей, St. Petersburg, 198515

N. Pestova

BIOCAD Biotechnological Company, poselok Strel’na

Хат алмасуға жауапты Автор.
Email: pestova@biocad.ru
Ресей, St. Petersburg, 198515

M. Petrova

BIOCAD Biotechnological Company, poselok Strel’na

Хат алмасуға жауапты Автор.
Email: petrovamv@biocad.ru
Ресей, St. Petersburg, 198515

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML

© Pleiades Publishing, Ltd., 2019